Company: Medivir (Sweden)
- nucleotide . MIV-818 is a liver-targeted nucleotide prodrug. This project is the first development project to emerge from Medivir’s in-house drug discovery efforts in oncology.
- • On January 8, 2018, Medivir announced the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018. The company now intends to make the necessary regulatory submissions during the first half of 2018, and to start the first clinical trials of MIV-818 during the second half of 2018.